Form 4: Director Akkaraju Boosts VTVT Stake with Warrants

Srinivas Akkaraju, a director of vTv Therapeutics Inc., reported significant acquisitions of common stock and warrants through affiliated funds.

Summary

• Srinivas Akkaraju, a director of vTv Therapeutics Inc., reported beneficial ownership changes through affiliated entities, Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P.
• On September 22, 2025, Samsara Opportunity Fund, L.P. acquired 106,000 shares of Class A Common Stock at a price of $15.265 per share.
• Samsara Opportunity Fund, L.P. also acquired pre-funded warrants exercisable for up to 877,214 shares of Class A Common Stock at an exercise price of $0.01.
• Additionally, Samsara Opportunity Fund, L.P. acquired common warrants exercisable for up to 983,214 shares of Class A Common Stock at an exercise price of $22.71.
• Following these transactions, Samsara Opportunity Fund, L.P. beneficially owns 106,000 shares of Class A Common Stock, 877,214 pre-funded warrants, and 983,214 common warrants.
• Samsara BioCapital, L.P. continues to beneficially own 206,784 shares of Class A Common Stock, 1,548,101 pre-funded warrants, and 655,523 common warrants.
• Mr. Akkaraju has voting and investment power over the securities held by both Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P., and disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: A director, through affiliated funds, made substantial purchases of company stock and warrants, indicating strong confidence in the company's future prospects.

Positives

• A director, through affiliated funds, made substantial purchases of company stock and warrants, signaling strong insider confidence in the company's future.
• The company received capital from the sale of these securities to Samsara Opportunity Fund, L.P.

Risks

• Holders of Pre-Funded Warrants and Common Warrants may not exercise them if, together with Attribution Parties, they would beneficially own more than 9.99% of the Class A Common Stock outstanding immediately after giving effect to such exercise.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company, as it is a report of insider transactions.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information to analyze broader industry trends or competitors.

Related Party Transactions

• Srinivas Akkaraju, a director of vTv Therapeutics Inc., has voting and investment power over securities held by Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P. The reported transactions involve Samsara Opportunity Fund, L.P. acquiring shares and warrants from the Issuer, making it a related party transaction due to the director's influence.

Stakeholder Impact

• Shareholders: The significant insider buying by a director through affiliated funds may be interpreted as a strong vote of confidence, potentially influencing positive market sentiment.
• Company: The sale of securities to Samsara Opportunity Fund, L.P. represents a capital infusion for the company.

Key Dates

Recommendation

The significant acquisition of common stock and warrants by a director, Srinivas Akkaraju, through affiliated investment funds, signals strong insider confidence in vTv Therapeutics Inc.'s future performance. This substantial investment suggests that those closest to the company believe its shares are undervalued or poised for growth, making it an attractive 'buy' signal for investors.

Keywords

vTv Therapeutics, VTVT, Srinivas Akkaraju, Insider Transaction, Stock Purchase, Warrants, Director